| Dr Corwin Ashford Thomas, DO | |
|
802 E Farrel Rd, Lafayette, LA 70508-7208 | |
| (337) 234-3163 | |
| (337) 234-3168 |
| Full Name | Dr Corwin Ashford Thomas |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 29 Years |
| Location | 802 E Farrel Rd, Lafayette, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013920362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 14733R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Jennings, LA | Home health agency |
| Byrd Regional Hospital | Leesville, LA | Hospital |
| Beauregard Memorial Hospital | Deridder, LA | Hospital |
| Sabine Medical Center | Many, LA | Hospital |
| Lafayette General Medical Center | Lafayette, LA | Hospital |
| Opelousas General Health System | Opelousas, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Louisiana Cardiovascular Associates, Llc | 3173908878 | 3 |
| Clhg-leesville | 4082963301 | 17 |
| Lafayette Cardiovascular Center Of Excellence,llc | 9931330370 | 4 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Corwin Ashford Gordon Thomas Pc, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437357647 PECOS PAC ID: 3971554940 Enrollment ID: O20050208000006 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Louisiana Cardiovascular And Limb Salvage Center, Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689825499 PECOS PAC ID: 8123181906 Enrollment ID: O20090106000605 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Lafayette Cardiovascular Center Of Excellence,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720423478 PECOS PAC ID: 9931330370 Enrollment ID: O20140327000945 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Southpark Surgery Center Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1770096273 PECOS PAC ID: 4082976907 Enrollment ID: O20180313000206 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Clhg-leesville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881665164 PECOS PAC ID: 4082963301 Enrollment ID: O20200310000179 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Entity Name | Louisiana Cardiovascular Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730823709 PECOS PAC ID: 3173908878 Enrollment ID: O20220916000272 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Corwin Ashford Thomas, DO 802 E Farrel Rd, Lafayette, LA 70508-7208 Ph: (337) 234-3163 | Dr Corwin Ashford Thomas, DO 802 E Farrel Rd, Lafayette, LA 70508-7208 Ph: (337) 234-3163 |
News Archive
According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).
Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.
Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.
An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 2 days ago
Dr. Maximo Bienvenido Lamarche, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 W Saint Mary Blvd, Lafayette, LA 70506 Phone: 337-233-6593 Fax: 337-235-1032 | |
Dr. John M Rainey, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 501 W Saint Mary Blvd, Lafayette, LA 70506 Phone: 337-235-7898 Fax: 337-235-7445 | |
Dr. Matthew Shane Fontenot, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1214 Coolidge Blvd, Lafayette, LA 70503 Phone: 337-289-7927 Fax: 337-289-7935 | |
Dr. John Brent Rhodes Jr., M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 439 Heymann Blvd, Lafayette, LA 70503 Phone: 337-269-0963 Fax: 337-269-0553 | |
Leela P. Lakshmiprasad, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Lsu Medicine Clinic, 2390 W Congress Street, Lafayette, LA 70506 Phone: 337-261-6100 | |
Dr. Kamalendra Nath Mondal, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3149 Ambassador Caffery Pkwy, Lafayette, LA 70506 Phone: 337-706-3415 |